Posted by Michael Wonder on 09 Nov 2017
Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus infection and disease in adult allogeneic stem cell transplant patients
8 November 2017 - Cytomegalovirus prophylaxis with Prevymis associated with lower all-cause mortality through week 24 and week 48 post-transplant.
Merck & Co today announced that the U.S. FDA has approved Prevymis (letermovir) once-daily tablets for oral use and injection for intravenous infusion. Prevymis is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
CMV is a common and potentially serious viral infection in allogeneic HSCT recipients. CMV-seropositive patients who undergo an HSCT are at high risk for CMV reactivation. Any level of CMV infection is associated with increased mortality in HSCT patients.
